Cargando…

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells

Triple negative breast cancer (TNBC) is an aggressive form of breast cancer which accounts for 15–20% of this disease and is currently treated with genotoxic chemotherapy. The BCL2 (B-cell lymphoma 2) family of proteins controls the process of mitochondrial outer membrane permeabilization (MOMP), wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucantoni, Federico, Lindner, Andreas U., O’Donovan, Norma, Düssmann, Heiko, Prehn, Jochen H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833806/ https://www.ncbi.nlm.nih.gov/pubmed/29352235 http://dx.doi.org/10.1038/s41419-017-0039-y

Ejemplares similares

BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose
por: Lucantoni, Federico, et al.
Publicado: (2018)

Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1
por: Lucantoni, Federico, et al.
Publicado: (2018)

Real-time single cell analysis of Smac/DIABLO release during apoptosis
por: Rehm, Markus, et al.
Publicado: (2003)

Mitochondrial Carrier Homolog 2 Functionally Co-operates With BH3 Interacting-Domain Death Agonist in Promoting Ca(2+)-Induced Neuronal Injury
por: D’Orsi, Beatrice, et al.
Publicado: (2021)

Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder
por: Guo, Jiawei, et al.
Publicado: (2016)

Single-cell time-lapse imaging of intracellular O(2) in response to metabolic inhibition and mitochondrial cytochrome-c release
por: Düssmann, Heiko, et al.
Publicado: (2017)

BOK controls ER proteostasis and physiological ER stress responses in neurons
por: Walter, Franziska, et al.
Publicado: (2022)

Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release
por: Huber, Heinrich J, et al.
Publicado: (2011)

Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer
por: Dowling, Catríona M., et al.
Publicado: (2021)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM
por: Juric, Viktorija, et al.
Publicado: (2021)

Anti-apoptotic BCL-2 family proteins in acute neural injury
por: Anilkumar, Ujval, et al.
Publicado: (2014)

Effect of TP53 deficiency and KRAS signaling on the bioenergetics of colon cancer cells in response to different substrates: A single cell study
por: Kealey, James, et al.
Publicado: (2022)

Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models
por: O’Farrell, Alice C., et al.
Publicado: (2020)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
por: Gaule, Patricia, et al.
Publicado: (2019)

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
por: Mukherjee, Nupur, et al.
Publicado: (2022)

Genotoxic effects of airborne agents
por: Tice, Raymund, et al.
Publicado: (1982)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Kanakaveti, Vishnupriya, et al.
Publicado: (2022)

Defining external factors that determine neuronal survival, apoptosis and necrosis during excitotoxic injury using a high content screening imaging platform
por: Anilkumar, Ujval, et al.
Publicado: (2017)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
por: Giordano, Antonio, et al.
Publicado: (2019)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

TRAIL signaling promotes entosis in colorectal cancer
por: Bozkurt, Emir, et al.
Publicado: (2021)

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress
por: Liu, Yanan, et al.
Publicado: (2022)

Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells
por: Rysanek, David, et al.
Publicado: (2022)

CISNE: An accurate description of dose-effect and synergism in combination therapies
por: García-Fuente, Amador, et al.
Publicado: (2018)

Ketone body β-hydroxybutyrate (BHB) preserves mitochondrial bioenergetics
por: Llorente-Folch, I., et al.
Publicado: (2023)

BH3-Only protein bmf is required for the maintenance of glucose homeostasis in an in vivo model of HNF1α-MODY diabetes
por: Pfeiffer, S, et al.
Publicado: (2015)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022)

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
por: Zhao, Na, et al.
Publicado: (2023)

Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer
por: Acton, Alexus, et al.
Publicado: (2023)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Increased Fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcome
por: Duggan, William P., et al.
Publicado: (2023)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer
por: Chen, Di, et al.
Publicado: (2019)

Individual susceptibility to genotoxic agents in the human population
por: Serres, Frederick, et al.
Publicado: (1984)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer
por: Skov, Natascha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c0s6aav1m6botqs0g9ed2km4lp